scholarly journals Gene Polymorphisms for Plasminogen Activator Inhibitor-1/Tissue Plasminogen Activator and Development of Allograft Coronary Artery Disease

Circulation ◽  
1998 ◽  
Vol 98 (21) ◽  
pp. 2248-2254 ◽  
Author(s):  
Raymond L. Benza ◽  
Hernan E. Grenett ◽  
Robert C. Bourge ◽  
James K. Kirklin ◽  
David C. Naftel ◽  
...  
1990 ◽  
Vol 63 (03) ◽  
pp. 336-339 ◽  
Author(s):  
K Huber ◽  
I Resch ◽  
Th Stefenelli ◽  
I Lang ◽  
P Probst ◽  
...  

SummaryIncreased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been shown to exist in 40 to 60% of patients with stable coronary artery disease and have been suggested to be responsible for the development of coronary thrombotic complications. However, it is also discussed whether PAI-1 elevation might mainly be due to variables like increased age or to reactive mechanisms caused e.g. by the chest pain itself. To exclude age dependent ui pain related influences, age-matched patients with stable angina pectoris (NHYA II) and angiographically proven coronary artery disease (CAD, n = 16) or without evidence for coronary sclerosis (variant angina, n = 10; angina-like syndrome with normal coronary angiogram, n = 5; non-CAD, n = 15) have been investigated for their plasma PAI-1 activity and t-PA antigen levels. The mean PAI activity in CAD patients (17.5 U/ml) was significantly higher than in non-CAD patients (9.6 U/ml) (p <0.0001). In the CAD patients no significant variation in plasma PAI-1 values could be demonstrated when related to the extent of the disease or to a history of previous myocardial infarction t-PA antigen was also elevated m CAD patients as compared to the non-CAD group (p <0.02). The results suggest therefore a strong correlation between coronary artery disease itself and elevated levels of components of the plasma fibrinolytic system.


Sign in / Sign up

Export Citation Format

Share Document